Abstract:Paradoxically, tumor development and progression can be inhibited and promoted by the immune system. After three stages of immune editing, namely, elimination, homeostasis and escape, tumor cells are no longer restricted by immune surveillance and thus develop into clinical tumors. The mechanisms of immune escape include abnormalities in antitumor-associated immune cells, selection for immune resistance to tumor cells, impaired transport of T cells, and the formation of an immunosuppressive tumor microenvironment. A population of distinct immature myeloid cells, myeloid-derived suppressor cells (MDSCs), mediate immune escape primarily by exerting immunosuppressive effects and participating in the constitution of an immunosuppressive microtumor environment. Clinical trials have found that the levels of MDSCs in the peripheral blood of cancer patients are strongly correlated with tumor stage, metastasis and prognosis. Moreover, animal experiments have confirmed that elimination of MDSCs inhibits tumor growth and metastasis to some extent. Therefore, MDSCs may become the target of immunotherapy for many cancers, and eliminating MDSCs can help improve the response rate to cancer treatment and patient survival. However, a clear definition of MDSCs and the specific mechanism involved in immune escape are lacking. In this paper, we review the role of the MDSCs population in tumor development and the mechanisms involved in immune escape in different tumor contexts. In addition, we discuss the use of these cells as targets for tumor immunotherapy. This review not only contributes to a systematic and comprehensive understanding of the essential role of MDSCs in immune system reactions against tumors but also provides information to guide the development of cancer therapies targeting MDSCs.

FOXP3+ regulatory T cells and the immune escape in solid tumours

Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects

Advance in the Study of CD4~+CD25~+FOXP3~+ Regulatory T Cell in Tumor Immune Evasion

Role of Immune Escape in Different Digestive Tumours

Why Treg should be the focus of cancer immunotherapy: The latest thought

Regulatory T cell: a protection for tumour cells.

The functional regulation of Treg and its role in anti-tumor immunotherapy

Regulatory T cell-mediated immunosuppression orchestrated by cancer: towards an immuno-genomic paradigm for precision medicine

Suppressive Myeloid Cells Shape the Tumor Immune Microenvironment

Advances in Foxp3+ regulatory T cells (Foxp3+ Treg) and key factors in digestive malignancies

Myeloid-derived suppressor cells in cancer: therapeutic targets to overcome tumor immune evasion

Understanding of Immune Escape Mechanisms and Advances in Cancer Immunotherapy.

T-cell infiltration and its regulatory mechanisms in cancers: insights at single-cell resolution

Regulatory T cells in cancer immunosuppression — implications for anticancer therapy

Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape

Next frontier in tumor immunotherapy: macrophage-mediated immune evasion

Investigating T Cell Immunity in Cancer: Achievements and Prospects

Metabolic reprogramming and immune evasion: the interplay in the tumor microenvironment

Noncoding RNAs: the Shot Callers in Tumor Immune Escape

Regulatory T cells and immune escape in HCC: understanding the tumor microenvironment and advancing CAR-T cell therapy

Stemness in solid malignancies: coping with immune attack